What you Missed at the Definitive Ion Channel Drug Development Forum in 2026
As investment surges and clinical momentum builds, the race is on to unlock the full therapeutic potential of ion channels across multiple indications.
The Ion Channel–Targeted Drug Development Summit brought together leading biopharma and academic innovators to tackle the field’s most pressing challenges, from subtype selectivity and safety to model-to-human translatability.
Through data-led case studies, cross-modality insights, and emerging platform technologies, you would have gained practical strategies to advance ion channel programs with confidence.
Engaged with pioneers from across discovery, translational science, and clinical development, and left equipped to accelerate your pipeline toward clinical success.
Event Highlights in 2026
Advancing Translational Strategies to Improve Clinical Success
Advancing Genetic & Nucleic Acid Approaches for Ion Channel Modulation
Leveraging Antibody-Based Strategies for Precise Ion Channel Targetin
Explore the 2026 Event Guide
- Get a complete snapshot of the agenda, key topics, and scientific focus areas across discovery to clinic
- Explore the cutting-edge themes shaping ion channel drug discovery, from electrophysiology to structural biology
- Preview the calibre of speakers and leading biopharma companies driving the next wave of innovation
- Understand how the summit tackles critical challenges like selectivity, translatability, and safety in ion channel development
- Easily share key event insights with colleagues to support internal alignment and attendance decisions
2026 Attending Companies Included
Explore the 2026 Agenda
Dive into cutting-edge ion channel strategies, from electrophysiology to clinical translation, across a data-packed program.
Partner With Us in 2027
Showcase your platforms, technologies, and services to senior decision-makers driving ion channel innovation.
Join Ion Channel Leaders
Connect with biopharma pioneers and scientific experts tackling selectivity, safety, and translational challenges head-on.